Free Trial
NASDAQ:SABS

SAB Biotherapeutics (SABS) Stock Price, News & Analysis

SAB Biotherapeutics logo
$1.95 -0.06 (-2.99%)
Closing price 04:00 PM Eastern
Extended Trading
$2.02 +0.07 (+3.38%)
As of 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About SAB Biotherapeutics Stock (NASDAQ:SABS)

Advanced

Key Stats

Today's Range
$1.89
$2.10
50-Day Range
$1.88
$2.79
52-Week Range
$1.00
$6.60
Volume
206,069 shs
Average Volume
280,757 shs
Market Capitalization
$20.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.75
Consensus Rating
Buy

Company Overview

SAB Biotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

SABS MarketRank™: 

SAB Biotherapeutics scored higher than 77% of companies evaluated by MarketBeat, and ranked 263rd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    SAB Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    SAB Biotherapeutics has a consensus price target of $9.75, representing about 400.0% upside from its current price of $1.95.

  • Amount of Analyst Coverage

    SAB Biotherapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about SAB Biotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for SAB Biotherapeutics are expected to grow in the coming year, from ($3.69) to ($2.98) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of SAB Biotherapeutics is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of SAB Biotherapeutics is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    SAB Biotherapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about SAB Biotherapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    5.25% of the float of SAB Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    SAB Biotherapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in SAB Biotherapeutics has recently decreased by 12.25%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    SAB Biotherapeutics does not currently pay a dividend.

  • Dividend Growth

    SAB Biotherapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.25% of the float of SAB Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    SAB Biotherapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in SAB Biotherapeutics has recently decreased by 12.25%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    SAB Biotherapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for SAB Biotherapeutics this week, compared to 1 article on an average week.
  • Search Interest

    8 people have searched for SABS on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added SAB Biotherapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, SAB Biotherapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    25.06% of the stock of SAB Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 7.82% of the stock of SAB Biotherapeutics is held by institutions.

  • Read more about SAB Biotherapeutics' insider trading history.
Receive SABS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SABS Stock News Headlines

Why More Investors Are Using Family Trusts to Protect Their Wealth
For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.tc pixel
Q3 Earnings Forecast for SABS Issued By Leerink Partnrs
SAB BIO Highlights Data in Multiple Presentations at EASD
See More Headlines

SABS Stock Analysis - Frequently Asked Questions

SAB Biotherapeutics' stock was trading at $3.79 on January 1st, 2025. Since then, SABS stock has decreased by 48.5% and is now trading at $1.95.

SAB Biotherapeutics, Inc. (NASDAQ:SABS) released its quarterly earnings data on Thursday, August, 7th. The company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.82) by $0.27.

Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that SAB Biotherapeutics investors own include ChargePoint (CHPT), PayPal (PYPL), Coinbase Global (COIN), Tesla (TSLA), Confluent (CFLT), CrowdStrike (CRWD) and Ford Motor (F).

Company Calendar

Last Earnings
8/07/2025
Today
9/29/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SABS
CIK
1833214
Fax
N/A
Employees
140
Year Founded
2014

Price Target and Rating

High Price Target
$12.00
Low Price Target
$7.00
Potential Upside/Downside
+400.0%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$34.10 million
Net Margins
N/A
Pretax Margin
-32,221.74%
Return on Equity
-153.92%
Return on Assets
-89.16%

Debt

Debt-to-Equity Ratio
0.27
Current Ratio
0.87
Quick Ratio
0.87

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.81 per share
Price / Book
0.69

Miscellaneous

Outstanding Shares
10,411,000
Free Float
7,802,000
Market Cap
$20.30 million
Optionable
Not Optionable
Beta
0.54

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:SABS) was last updated on 9/29/2025 by MarketBeat.com Staff
From Our Partners